Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis
Authors' conclusion
Continued clinical improvement during prolonged rilonacept treatment corresponded with improvement on CMR, including reduced pericardial thickness, resolution of pericardial oedema, and resolution of LGE. However, none/trace LGE at 18MDM while on treatment did not predict absence of pericarditis recurrence upon subsequent rilonacept suspension in this size-limited subgroup.
Study context
- Population
- Patients with recurrent pericarditis treated with rilonacept in the RHAPSODY long-term extensionCardiac magnetic resonance (CMR) at baseline and 18MDM
- Participants
- 13 patients
- Comparison
- CMR at baseline vs 18-month decision milestone during rilonacept treatment
- Primary endpoint
- Change in CMR findings (pericardial thickness, pericardial oedema [T2-STIR], LGE) and pericarditis recurrence after rilonacept suspension
- Follow-up
- Baseline and 18-month decision milestone (18MDM)
Methodological detailssubgroup analysis, long-term extension, imaging core lab blinded to clinical data
- Subgroup analysis
- Long-term extension
- Imaging core lab blinded to clinical data
Primary result
As reported in the abstract
Pericarditis recurrence within 1-4 months of rilonacept suspension at 18MDM, despite none/trace late gadolinium enhancement (LGE) and negative T2-STIR at 18MDM in all (n = 7)
5
71%
Original publication
Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis. Eur Heart J Cardiovasc Imaging. Published 22 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →